Voyager Therapeutics (VYGR) Other Non Operating Income (2016 - 2026)

Voyager Therapeutics has disclosed Other Non Operating Income across 11 years of filings, most recently posting $435000.0 for Q1 2026.

• Other Non Operating Income for Q1 2026 came in at $435000.0, up 4.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (up 60.19% YoY), and the FY2025 annual result was $1.6 million, up 165.11% from the prior year.
• Other Non Operating Income came in at $435000.0 for Q1 2026 at Voyager Therapeutics, up from $404000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $2.6 million in Q3 2022 to a low of -$23000.0 in Q4 2022.
• The 5-year median for Other Non Operating Income is $401000.0 (2024), against an average of $448666.7.
• Peak annual rise in Other Non Operating Income reached 2454.46% in 2022, while the deepest fall reached 103.54% in 2022.
• Voyager Therapeutics' Other Non Operating Income stood at -$23000.0 in 2022, then jumped by 113.04% to $3000.0 in 2023, then soared by 13300.0% to $402000.0 in 2024, then grew by 0.5% to $404000.0 in 2025, then gained by 7.67% to $435000.0 in 2026.
• The last three Other Non Operating Income figures came in at $435000.0 (Q1 2026), $404000.0 (Q4 2025), and $400000.0 (Q3 2025), per Business Quant data.